[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK277985A - GLYCOPROTEIN WITH ANTITUMORAL EFFECT AND PROCEDURE FOR PREPARING THEREOF - Google Patents

GLYCOPROTEIN WITH ANTITUMORAL EFFECT AND PROCEDURE FOR PREPARING THEREOF Download PDF

Info

Publication number
DK277985A
DK277985A DK277985A DK277985A DK277985A DK 277985 A DK277985 A DK 277985A DK 277985 A DK277985 A DK 277985A DK 277985 A DK277985 A DK 277985A DK 277985 A DK277985 A DK 277985A
Authority
DK
Denmark
Prior art keywords
glycoprotein
antitumoral
preparing
procedure
antitumoral effect
Prior art date
Application number
DK277985A
Other languages
Danish (da)
Other versions
DK166626B1 (en
DK277985D0 (en
Inventor
Franz Jansen
Pierre Gros
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8409703A external-priority patent/FR2566271B1/en
Priority claimed from FR8502067A external-priority patent/FR2577137B1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DK277985D0 publication Critical patent/DK277985D0/en
Publication of DK277985A publication Critical patent/DK277985A/en
Application granted granted Critical
Publication of DK166626B1 publication Critical patent/DK166626B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

1. Claims for the contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE Antitumoral glycoprotein which inactives ribosomes, whose carbohydrate units are modified by oxidation with the periodate ion, said glycoprotein differing from the whole ricin. 1. Claims for contracting State : AT Process for the obtention of an antitumoral glycoprotein whose carbohydrate units are modified, said glycoprotein differing from the whole ricin, characterized in that it consists in submitting an unmodified antitumoral glycoprotein to an oxydation with periodate ions.
DK277985A 1984-06-20 1985-06-19 ANTITUMORAL GLYCOPROTEINS, WHETHER CARBOHYDRATE UNITS HAVE BEEN MODIFIED, AND METHOD OF PRODUCING THEREOF. DK166626B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8409703A FR2566271B1 (en) 1984-06-20 1984-06-20 NOVEL CYTOTOXIC CONJUGATES FOR USE IN THERAPEUTICS AND PROCESS FOR OBTAINING SAME
FR8409703 1984-06-20
FR8502067 1985-02-13
FR8502067A FR2577137B1 (en) 1985-02-13 1985-02-13 ANTI-TUMOR GLYCOPROTEINS, MODIFIED ON THEIR CARBOHYDRATES

Publications (3)

Publication Number Publication Date
DK277985D0 DK277985D0 (en) 1985-06-19
DK277985A true DK277985A (en) 1985-12-21
DK166626B1 DK166626B1 (en) 1993-06-21

Family

ID=26224020

Family Applications (1)

Application Number Title Priority Date Filing Date
DK277985A DK166626B1 (en) 1984-06-20 1985-06-19 ANTITUMORAL GLYCOPROTEINS, WHETHER CARBOHYDRATE UNITS HAVE BEEN MODIFIED, AND METHOD OF PRODUCING THEREOF.

Country Status (14)

Country Link
EP (1) EP0172045B1 (en)
JP (1) JPS6112628A (en)
KR (1) KR930000058B1 (en)
AT (1) ATE40700T1 (en)
AU (1) AU593211B2 (en)
CA (1) CA1248874A (en)
DE (1) DE3568167D1 (en)
DK (1) DK166626B1 (en)
ES (1) ES8605681A1 (en)
GR (1) GR851497B (en)
IE (1) IE58514B1 (en)
IL (1) IL75484A0 (en)
NZ (1) NZ212439A (en)
PT (1) PT80662B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2577135B1 (en) * 1985-02-13 1989-12-15 Sanofi Sa LONG-TERM ACTION IMMUNOTOXINS COMPRISING A GLYCOPEPTITIDE CONSTITUENT MODIFYING RIBOSOMES MODIFIED ON ITS POLYSACCHARIDE PATTERNS
US4911912A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and reduction, and in vivo prolonged-action immunotoxins containing such a glycoprotein
FR2602682B1 (en) * 1986-08-12 1988-12-02 Sanofi Sa LONG-DURING IN VIVO IMMUNOTOXINS COMPRISING A RIBOSOME INHIBITING GLYCOPROTEIN MODIFIED BY OXIDATION OF OSID PATTERNS AND FORMATION OF A SCHIFF BASE
FR2601679B1 (en) * 1986-07-15 1990-05-25 Sanofi Sa IMMUNOTOXINS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
DE4106389A1 (en) * 1991-02-28 1992-09-03 Behringwerke Ag FUSION PROTEINS FOR PRODRUG ACTIVATION, THEIR PRODUCTION AND USE
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US5250532A (en) * 1991-04-11 1993-10-05 Dowelanco 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
GB9808485D0 (en) * 1998-04-21 1998-06-17 Univ Cambridge Tech Improvements relating to immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
FR2437213A1 (en) * 1978-09-28 1980-04-25 Cm Ind CYTOTOXIC PRODUCTS FORMED BY COVALENT BINDING OF THE CHAIN TO RICIN WITH AN ANTIBODY AND THEIR PREPARATION METHOD
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS5843926A (en) * 1981-09-08 1983-03-14 Suntory Ltd Selective carcinostatic agent

Also Published As

Publication number Publication date
KR930000058B1 (en) 1993-01-06
GR851497B (en) 1985-11-25
DE3568167D1 (en) 1989-03-16
AU593211B2 (en) 1990-02-08
IL75484A0 (en) 1985-10-31
KR860000315A (en) 1986-01-28
AU4364685A (en) 1986-01-02
ATE40700T1 (en) 1989-02-15
EP0172045B1 (en) 1989-02-08
JPH0582400B2 (en) 1993-11-18
EP0172045A1 (en) 1986-02-19
PT80662A (en) 1985-07-01
NZ212439A (en) 1989-01-27
ES8605681A1 (en) 1986-04-01
CA1248874A (en) 1989-01-17
IE851511L (en) 1985-12-20
ES544337A0 (en) 1986-04-01
IE58514B1 (en) 1993-10-06
JPS6112628A (en) 1986-01-21
PT80662B (en) 1986-12-09
DK166626B1 (en) 1993-06-21
DK277985D0 (en) 1985-06-19

Similar Documents

Publication Publication Date Title
ZA871335B (en) New aryl-substituted(n-piperidinyl)methyl-and(n-piperazinyl)-methylazoles having antipsychotic properties
ES8502476A1 (en) DNA sequences, recombinant DNA molecules and processes for producing bovine growth hormone-like polypeptides in high yield.
PT73259B (en) Process for preparing novel substituted pyrazinyl-1,2,4-oxadiazole-5-ones
PT76546A (en) Process for preparing functional human urokinase protein
DK277985A (en) GLYCOPROTEIN WITH ANTITUMORAL EFFECT AND PROCEDURE FOR PREPARING THEREOF
JPS57134465A (en) Manufacture of 1,5-didesoxy-1,5-imino-d- glucitol or n-derivative thereof
AU573531B2 (en) Human lymphotoxin
IL75133A (en) Process for the preparation of 1,2-diacyl-s,n-glycerophosphocholines(or glycerophosphoethanolamines)and some novel intermediates therefor
SG33647G (en) Steroidal 17alpha-silyl ethers and process to corticoids and progesterones
IE890607L (en) Antihypertensive hyperimmune milk, production, composition, and use
EP0244189A3 (en) Human pancreatic elastase i
ES8705496A1 (en) Process for recovering poly(arylene sulfides).
MY105082A (en) Separation process
IT8622286A0 (en) PROCEDURE FOR THE REFINING OF COAL BY MEANS OF SELECTIVE AGGLOMERATING.
DE3161613D1 (en) Process for the production of 3-mercapto-propanediol-(1,2)
JPS5241605A (en) Coal gasification apparatus
JPS5214518A (en) Process for manufacturing a rotatable drum for the centrifugal separat or for concentrating uranium
JPS57192330A (en) Manufacture of 3,3-dimethylglutaric acid
JPS51139680A (en) Method for purifing enzyme
YU42730B (en) Process for achieving low sulfur concentrations (below 0.02%) in directly reduced iron
EP0081831A3 (en) Process for purifying elastase
Gershkovich et al. Refining Copper from Hydrogen by Blowing Off with an Inert Gas
KRUGER et al. INFLUENCE OF CONTAMINATION BY PLASTER ON CERAMIC SHAPING IN THE FIRM VEB HENNEBERG-PORZELLAN
Prince Innovation for the Eighties[in the South African Steel Industry]
JPS5223361A (en) Process for controlling a gas concentration in a conservatory

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed